Genomic Landscape of Patients with Germline RUNX1 Variants and Familial Platelet Disorder with Myeloid Malignancy

Germline RUNX1 mutations lead to familial platelet disorder with associated myeloid malignancies (FPDMM), which is characterized by thrombocytopenia and a life-long risk (35-45%) of hematological malignancies. We recently launched a longitudinal natural history study for patients with FPDMM at the NIH Clinical Center. Among 29 families with research genomic data, 28 different germline RUNX1 variants were detected. Besides missense mutations enriched in Runt homology domain and loss-of-function mutations distributed throughout the gene, splice-region mutations and large deletions were detected in 6 and 7 families, respectively. In 24 of 54 (44.4%) non-malignant patients, somatic mutations were detected in at least one of the clonal hematopoiesis of indeterminate potential (CHIP) genes or acute myeloid leukemia (AML) driver genes. BCOR was the most frequently mutated gene (in 9 patients), and multiple BCOR mutations were identified in 4 patients. Mutations in 7 other CHIP or AML driver genes (DNMT3A, TET2, NRAS, SETBP1, SF3B1, KMT2C, and LRP1B) were also found in more than one non-malignant patient. Moreover, three unrelated patients (one with myeloid malignancy) carried somatic mutations in NFE2, which regulates erythroid and megakaryocytic differentiation. Sequential sequencing data from 19 patients demonstrated dynamic changes of somatic mutations over time, and stable clones were more frequently found in elderly patients. In summary, there are diverse types of germline RUNX1 mutations and high frequency of somatic mutations related to clonal hematopoiesis in patients with FPDMM. Monitoring dynamic changes of somatic mutations prospectively will benefit patients’ clinical management and reveal mechanisms for progression to myeloid malignancies. Key Points Comprehensive genomic profile of patients with FPDMM with germline RUNX1 mutations. Rising clonal hematopoiesis related secondary mutations that may lead to myeloid malignancies.

[1]  E. Clappier,et al.  Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN). , 2021, Blood.

[2]  M. Loh,et al.  Germline RUNX1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia , 2021, medRxiv.

[3]  Ivana V. Yang,et al.  Author Correction: Inherited causes of clonal haematopoiesis in 97,691 whole genomes , 2021, Nature.

[4]  Nicholas D. Camarda,et al.  Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome , 2021, Nature Communications.

[5]  S. Jaiswal.  Clonal hematopoiesis and non-hematologic disorders. , 2020, Blood.

[6]  Anna L. Brown,et al.  RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. , 2020, Blood advances.

[7]  B. Ebert,et al.  Clonal hematopoiesis in human aging and disease , 2019, Science.

[8]  M. McMullin,et al.  Somatic SF3B1 mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia , 2019, Journal of Clinical Pathology.

[9]  P. Libby,et al.  Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease , 2019, Nature Reviews Cardiology.

[10]  Mark Barnes,et al.  SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events , 2019, BMC Genomics.

[11]  L. Alberio,et al.  Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders , 2019, Journal of thrombosis and haemostasis : JTH.

[12]  D. Steinemann,et al.  Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. , 2019, Blood.

[13]  T. Hirano,et al.  Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. , 2019, Immunity.

[14]  D. Baeten,et al.  The inflammatory function of human IgA , 2018, Cellular and Molecular Life Sciences.

[15]  Jong-Bok Yoon,et al.  KDM3A histone demethylase functions as an essential factor for activation of JAK2−STAT3 signaling pathway , 2018, Proceedings of the National Academy of Sciences.

[16]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[17]  P. Campbell,et al.  Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers , 2017, bioRxiv.

[18]  D. Baeten,et al.  Serum IgA Immune Complexes Promote Proinflammatory Cytokine Production by Human Macrophages, Monocytes, and Kupffer Cells through FcαRI–TLR Cross-Talk , 2017, The Journal of Immunology.

[19]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[20]  P. Noris,et al.  Mutations of RUNX1 in families with inherited thrombocytopenia , 2017, American journal of hematology.

[21]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[22]  R. Sood,et al.  Role of RUNX1 in hematological malignancies. , 2017, Blood.

[23]  M. D. de Bruijn,et al.  Runx transcription factors in the development and function of the definitive hematopoietic system. , 2017, Blood.

[24]  X. Liu,et al.  A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy , 2017, Leukemia.

[25]  Anna L. Brown,et al.  Recognition of familial myeloid neoplasia in adults. , 2017, Seminars in hematology.

[26]  Helen E. Parkinson,et al.  The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog) , 2016, Nucleic Acids Res..

[27]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[28]  O. Abdel-Wahab,et al.  Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia , 2016, Leukemia.

[29]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[30]  L. Zon,et al.  Dynamic Control of Enhancer Repertoires Drives Lineage and Stage-Specific Transcription during Hematopoiesis. , 2016, Developmental cell.

[31]  Christopher A. Miller,et al.  Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. , 2015, Blood.

[32]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[33]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[34]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[35]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[36]  L. Godley.  Inherited predisposition to acute myeloid leukemia. , 2014, Seminars in hematology.

[37]  U. Testa,et al.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.

[38]  B. Göttgens,et al.  Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes. , 2013, Blood.

[39]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[40]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[41]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[42]  Stuart A. Wilson,et al.  TREX exposes the RNA binding domain of Nxf1 to enable mRNA export , 2012, Nature Communications.

[43]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[44]  A. Gruber,et al.  P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. , 2011, The Journal of clinical investigation.

[45]  W. Ouwehand,et al.  Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators , 2011, Developmental cell.

[46]  H. Pahl,et al.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. , 2009, Blood.

[47]  Joseph T. Glessner,et al.  PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. , 2007, Genome research.

[48]  T. Hirano.  At the heart of the chromosome: SMC proteins in action , 2006, Nature Reviews Molecular Cell Biology.

[49]  Yoshiaki Ito,et al.  In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. , 2002, Blood.

[50]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.